Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona)
Valentina Mazzotta,Silvia Nozza,Simone Lanini,Davide Moschese,Alessandro Tavelli,Roberto Rossotti,Francesco Maria Fusco,Lorenzo Biasioli,Giulia Matusali,Angelo Roberto Raccagni,Davide Mileto,Chiara Maci,Giuseppe Lapadula,Antonio Di Biagio,Luca Pipitò,Enrica Tamburrini,Antonella d'Arminio Monforte,Antonella Castagna,Andrea Antinori,mpox-Icona study group,Spinello Antinori,Chiara Baiguera,Gianmaria Baldin,Matteo Bassetti,Paolo Bonfanti,Giorgia Brucci,Elena Bruzzesi,Caterina Candela,Antonio Cascio,Andrea Delama,Gabriella D'Ettorre,Damiano Farinacci,Maria Rita Gismondo,Andrea Gori,Massimiliano Lanzafame,Miriam Lichtner,Giulia Mancarella,Alessandro Mancon,Giulia Marchetti,Emanuele Nicastri,Alessandro Pandolfo,Francesca Panzo,Stefania Piconi,Carmela Pinnetti,Alessandro Raimondi,Marco Ridolfi,Giuliano Rizzardini,Alessandra Rodanò,Margherita Sambo,Vincenzo Sangiovanni,Nadia Sangiovanni,Daniele Tesoro,Serena Vita
DOI: https://doi.org/10.1016/j.ebiom.2024.105289
IF: 11.205
2024-08-22
EBioMedicine
Abstract:Background: Severe and prolonged mpox courses have been described during the 2022-2023 outbreak. Identifying predictors of severe evolution is crucial for improving management and therapeutic strategies. We explored the predictors of mpox severity and tested the association between mpox severity and viral load in biological fluids. We also analysed the predictors of disease duration and kinetics of inflammatory markers and described the viral presence and duration of shedding in biological fluids. Methods: This multicentre historical cohort study included adults diagnosed with laboratory-confirmed mpox diagnosis between May 2022 and September 2023 at 15 Italian centres. Patients were followed up from the day of diagnosis until clinical recovery. Biological fluids (blood, urine, saliva, and oropharyngeal and rectal swabs) were collected from each subgroup during the course of the disease and after healing. The primary outcomes were disease severity (presence of mucosal involvement, extended rash, or need for hospitalisation) and its association with the cycle threshold value (Ct-value, surrogate of viral load) in biological fluids, using standard linear and linear mixed-effect logistic regression models. Among the secondary outcomes, predictors of disease duration were assessed using a linear regression model. Findings: A total of 541 patients were enrolled, including four (0.74%) women, with a median age of 38 years (IQR 33-44). Among the 235 people living with HIV (PLWH) (43.44%), 22 (4.07%) had a CD4 count lower than 350 cells/μL. Severe mpox was reported in 215 patients (39.74%). No patient died. Multivariable analysis showed that, severe mpox was more likely among Caucasians (OR 1.82; 95% CI 1.14-2.90, p = 0.012) and patients who had an onset of fever (1.95; 1.27-2.99, p = 0.002), lymphadenopathy (2.30; 1.52-3.48, p < 0.001), sore throat (2.14; 1.27-3.59, p = 0.004), and peri-anal lesions (2.91; 1.93-4.37, p < 0.001). There was a significant difference (p = 0.003) between the median Ct-value in the upper respiratory tract for patients presenting with either mild (35.15; IQR 28.77-42.01) or severe infection (31.00; 25.00-42.01). The risk of developing severe disease decreased by approximately 5% per Ct increase (0.95; 0.91-0.98; p = 0.005). The disease lasted longer in the case of proctitis (+4.78 days; 1.95-7.61, p = 0.001), sore throat (+3.12; 0.05-6.20, p = 0.046), extended rash (+3.42; 0.55-6.28, p = 0.020), as well as in PLWH with a low CD4 count (+12.51; 6.79-18.22, p < 0.001). Interpretation: The identification of predictors of severe or prolonged disease and the direct association MPXV Ct-value in the upper respiratory tract and disease severity could be useful in establishing proper management and early treatment of new mpox cases. Funding: ICONA Foundation; Italian Ministry of Health "Ricerca Corrente Linea 2", INMI Lazzaro Spallanzani IRCCS.